Jessica Cho
Internal Medicine · Los Angeles, CANPI 1023162039
Payments from drug & device makers
Across 303 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$892
- Lilly USA, LLC$873
- Amgen$798
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,48599%
- Education$521%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 46 | $1,331 |
| AbbVie(2 entities) | 34 | $1,302 |
| Novo Nordisk | 32 | $1,087 |
| AstraZeneca | 35 | $892 |
| Lilly USA, LLC | 32 | $873 |
| Amgen(2 entities) | 17 | $798 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $314 |
| Johnson & Johnson | 11 | $305 |
| Abbott | 8 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $264 |
| Corcept Therapeutics | 5 | $218 |
| Jazz Pharmaceuticals Inc. | 2 | $207 |
| Astellas Pharma US Inc | 9 | $201 |
| Bayer | 3 | $173 |
| Axsome Therapeutics, Inc. | 2 | $172 |
| Merck | 3 | $159 |
| Ivantis, Inc | 1 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $119 |
| Pfizer | 5 | $112 |
| Supernus Pharmaceuticals, Inc. | 6 | $107 |
| Exact Sciences | 3 | $86 |
| Arbor Pharmaceuticals, Inc. | 4 | $81 |
| IBSA Pharma Inc. | 3 | $66 |
| Adlon Therapeutics L.p. | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $53 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $31 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| GSK | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,554 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $20,760 |
| OzempicSemaglutide | 20 | $17,171 |
| Propranolol Hcl | 19 | $341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $873 | $20,76020 claims |
| Novo NordiskOzempic | $1,087 | $17,17120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.